flow semaglutide clinical trial could be 'practice changing' for adults with diabetes, CKD Effects of Semaglutide on CKD

In appropriate patients, medically supervised GLP-1 therapy has been associated with: Sustained weight reduction over time Improvements in A1C and overall blood sugar in people with type 2 diabetes Reduced waist circumference and visceral fat Better blood pressure, cholesterol, and other metabolic markers In some studies with Wegovy, a reduced risk of certain serious cardiovascular events in adults with obesity and existing heart disease At NuIQ, the goal of our GLP-1 semaglutide program is not just fast weight lossits sustainable weight management, better energy, and long-term metabolic health, all under the guidance of licensed medical professionals

Using the GLP-QR agonist Exendin-4 (Exn-4) increased firing rates in arcuate nucleus (ARC) GLP-1R and POMC neurons, and the chemogenetic activation of ARC GLP-1R neurons significantly reduced food intake [132]

SaccoRLKasnerSEBroderickJPCaplanLRConnorsJJCulebrasAet al

[DOI] [PubMed] [Google Scholar] 49.Facciorusso A., Straus Takahashi M., Eyileten Postula C., Buccino V.R., Muscatiello N

By fostering open discussions about this topic, we can encourage more people to seek help and find effective solutions to manage their symptoms